DV Trading LLC purchased a new stake in Pharvaris N.V. (NASDAQ:PHVS – Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 143,966 shares of the company’s stock, valued at approximately $4,067,000. Pharvaris accounts for approximately 0.1% of DV Trading LLC’s portfolio, making the stock its 12th biggest holding.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new position in Pharvaris during the fourth quarter worth $35,000. JPMorgan Chase & Co. grew its position in shares of Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares during the period. Barclays PLC acquired a new stake in shares of Pharvaris in the fourth quarter valued at about $77,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Pharvaris during the fourth quarter worth about $86,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Pharvaris during the fourth quarter worth about $110,000.
Insider Activity at Pharvaris
In related news, CFO David W. Nassif sold 10,000 shares of the company’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $30.31, for a total transaction of $303,100.00. Following the completion of the sale, the chief financial officer owned 120,300 shares of the company’s stock, valued at approximately $3,646,293. This represents a 7.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the completion of the sale, the director owned 315,167 shares of the company’s stock, valued at approximately $11,185,276.83. The trade was a 8.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 178,322 shares of company stock worth $5,969,286 in the last 90 days. 11.84% of the stock is owned by insiders.
Pharvaris Stock Down 3.7%
Pharvaris (NASDAQ:PHVS – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. On average, research analysts anticipate that Pharvaris N.V. will post -2.97 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on PHVS. Citizens Jmp reduced their price target on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 13th. Wolfe Research began coverage on Pharvaris in a report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price objective on the stock. Royal Bank Of Canada cut their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Wall Street Zen cut Pharvaris from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Finally, Morgan Stanley raised their target price on Pharvaris from $41.00 to $46.00 and gave the company an “overweight” rating in a research report on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Pharvaris presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.08.
View Our Latest Analysis on PHVS
Pharvaris Company Profile
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Featured Stories
- Five stocks we like better than Pharvaris
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Want to see what other hedge funds are holding PHVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pharvaris N.V. (NASDAQ:PHVS – Free Report).
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
